Nightstar Therapeutics plc (NITE) IPO Opens Up 23%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil settles up 2% after Trump rejects return to Iran ceasefire deal terms
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Revolution Medicines prices RASONQUE at $39,800 per month
Nightstar Announces Pricing of Initial Public Offering
September 27, 2017 7:45 PM EDTLEXINGTON, Mass. & LONDON--(BUSINESS WIRE)-- Nightstar Therapeutics plc (Nightstar or the Company), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, today announced the pricing of its initial public offering in the United States of 5,360,000 American Depositary Shares (ADSs) representing 5,360,000 ordinary shares at an initial public offering price of $14.00 per ADS for total gross proceeds of approximately $75.0 million. All ADSs sold in the offering were offered by Nightstar. The shares are expected to begin trading on The NASDAQ Global Select Market on September 28, 2017 under the ticker symbol NITE. In addition, Nightstar has granted the underwriters a 30-day option to... More
